RxDoctor Payments Data

Brian Elrod, MD

Family Medicine · Montgomery, ALNPI 1508847963

Payments from drug & device makers

$6,909in general payments, 2019–2025

Across 423 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$766
  • Pfizer$695
  • AstraZeneca$669
  • AbbVie$492
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$489
  • Lilly USA, LLC$470
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,84499%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,909 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$179,425
Medicare patients
233
Services billed
7,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$168,198
OzempicSemaglutide117$159,762
MounjaroTirzepatide96$143,923
JardianceEmpagliflozin98$89,119
FarxigaDapagliflozin Propanediol60$62,091
MyrbetriqMirabegron72$61,712
TrulicityDulaglutide35$46,579
VascepaIcosapent Ethyl60$45,749
XareltoRivaroxaban34$34,054
RybelsusSemaglutide16$24,210
Icosapent Ethyl37$19,582
LinzessLinaclotide23$17,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,986
JanuviaSitagliptin Phosphate12$15,642
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$15,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$470$190,501131 claims
Novo NordiskOzempic, Rybelsus$766$183,972133 claims
PfizerEliquis, Premarin$695$176,539172 claims
Boehringer IngelheimJardiance$36$89,11998 claims
AstraZenecaFarxiga$669$62,09160 claims
Astellas Pharma US IncMyrbetriq$192$61,71272 claims
MerckJanuvia, Belsomra, Janumet$128$35,46954 claims
Johnson & JohnsonXarelto$286$34,05434 claims
AbbVieLinzess, Synthroid, Savella$492$31,573122 claims
GSKTrelegy Ellipta$277$16,98617 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$489$13,97412 claims
Eisai Inc.Dayvigo$95$10,85627 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →